Decision Diagnostics signs manufacturing and R+D agreement for its proprietary blood glucose test strip with a Korean manufacturer.
M2 EQUITYBITES-June 5, 2015-Decision Diagnostics signs manufacturing and R+D agreement for its proprietary blood glucose test strip with a Korean manufacturer
(C)2015 M2 COMMUNICATIONS http://www.m2.com
Diagnostics products company Decision Diagnostics (OTC PINK:DECN) revealed on Thursday the launch of manufacturing and R+D agreement to supplement the supply of its proprietary blood glucose test strip through a Korean manufacturer.
Under the agreement, Decision Diagnostics' subsidiary Pharma Tech Solutions made a cash investment in the Korean manufacturer.
This partnership calls for enhanced manufacturing of Decision's GenStrip 50, a new product for in-home pet testing, completion of discretion concept product as well as the addition of a glucose meter using GenStrip 50 for international markets.
According to the company, GenStrip 50 is the US FDA cleared green glucose test strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters.
The agreement encompasses the co-development of multiple internally designed new products, a market ready meter system that uses Decision's proprietary blood glucose test strip in export markets as well as the distribution of an existing glucose monitoring system to the domestic at-home pet testing market.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jun 5, 2015|
|Previous Article:||Wheeler Real Estate Investment Trust announces acquisition of Brook Run Shopping Center in Richmond, Virginia.|
|Next Article:||Santander Foundation makes donation to Dartmoor Zoological Society.|